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1,2 Measurement of flow-mediated vasodilation (FMD) of the brachial artery is a useful method for assessing endothelial function in humans. [3] [4] [5] [6] [7] [8] [9] [10] Appropriate interventions, including pharmacological therapy, supplementation therapy, and lifestyle modifications, are effective for improving endothelial function assessed by FMD in patients with cardiovascular diseases. [11] [12] [13] [14] [15] [16] In addition, several lines of evidence have shown that FMD is an independent predictor of future cardiovascular events.
arteries is associated with increased risk of cardiovascular events. These findings suggest that nitroglycerine-induced vasodilation may be not only a control test for FMD measurement but also a useful marker of the grade of atherosclerosis.
Although it is well known that FMD is an independent predictor of future cardiovascular events, some studies have shown that FMD is not associated with future cardiovascular events in cases of a relatively low grade of atherosclerosis and in cases of a severe stage of atherosclerosis after adjusting for various confounders. [17] [18] [19] [20] [21] [22] 28, 29 The reasons for the discrepant results remain unclear.
It is expected that nitroglycerine-induced vasodilation would predict future cardiovascular events. The combination of measurements of FMD and nitroglycerine-induced vasodilation would be a more useful biomarker reflecting vascular function and would improve the predictive value of future cardiovascular events compared with measurement of FMD alone. In this study, we evaluated the prognostic values of measurements of FMD alone, nitroglycerine-induced vasodilation alone, and FMD combined with nitroglycerine-induced vasodilation for future cardiovascular events.
Methods

Subjects
Between July 2007 and October 2013, a total of 402 subjects were enrolled from people who underwent health-screening examinations at Hiroshima University Hospital. All subjects have an obligation to undergo health screening every year under regulation of the societymanaged health insurance union in Japan. Hypertension was defined as systolic blood pressure of >140 mm Hg and diastolic blood pressure of >90 mm Hg, in a sitting position, on at least 3 different occasions. Normotension was defined as systolic blood pressure of <140 mm Hg and diastolic blood pressure of <90 mm Hg. Diabetes mellitus was defined according to the American Diabetes Association or a previous diagnosis of diabetes mellitus. 30 Dyslipidemia was defined according to the third report of the National Cholesterol Education Program. 31 Framingham risk score was calculated by the following points of risk factors: age, total cholesterol level, high-density lipoprotein cholesterol level, systolic blood pressure, and smoking status. 32 The ethical committees of our institutions approved the study protocol. Written informed consent for participation in the study was obtained from all subjects.
Study Protocol
We assessed vascular function by measurements of FMD and nitroglycerine-induced vasodilation in all subjects. Subjects were instructed to abstain from eating, alcohol, smoking, and caffeine for at least 12 hours before the measurements. The subjects were kept in the supine position in a quiet, dark, air-conditioned room (constant temperature of 22°C-25°C) throughout the study. A 23-gauge polyethylene catheter was inserted into the left deep antecubital vein to obtain blood samples. Thirty minutes after resting in the supine position, FMD and nitroglycerine-induced vasodilation were measured.
From December 2013 to May 2014, we collected the information on potential outcomes or adverse events from medical records and from 1 telephone survey. We obtained complete follow-up data on 402 subjects. We first assessed the associations of FMD alone, nitroglycerine-induced vasodilation alone, and FMD combined with nitroglycerine-induced vasodilation and first major cardiovascular events (death from cardiovascular causes, acute myocardial infarction, stroke, and coronary revascularization) and then assessed the associations with death from cardiovascular causes, acute myocardial infarction, stroke, coronary revascularization, and hospitalization for heart failure.
Measurement of FMD and Nitroglycerine-Induced Vasodilation
A high-resolution ultrasonography equipment (UNEXEF18G; UNEX Co, Nagoya, Japan) was used to evaluate FMD and nitroglycerine-induced vasodilation. 10, 27 Additional details are available in the online-only Data Supplement.
Statistical Analysis
Because there is no previous study investigating the association between FMD combined with nitroglycerine-induced vasodilation and cardiovascular events, we enrolled all subjects in whom vascular function was assessed. Some variables in the data set had missing data: body mass index (BMI, n=2), serum concentrations of total cholesterol (n=10), triglycerides (n=11), high-density lipoprotein cholesterol (n=10), low-density lipoprotein cholesterol (n=10), glucose (n=50), and Framingham risk score (n=10). Missing data were not imputed and all continuous variables were analyzed using observed-case analysis. Results are presented as means±SD for continuous variables and as percentages for categorical variables. Statistical significance was set at a level of P<0.05. Continuous variables were compared by using ANOVA for multiple groups. Categorical variables were compared by means of the χ 2 test. The receiver-operator characteristic curve analyses were performed to assess the sensitivity and specificity of measurement of FMD alone, nitroglycerine-induced vasodilation alone, and FMD combined with nitroglycerine-induced vasodilation for predicting first major cardiovascular events. To take time-to-event into consideration, we calculated the Harrell C index. 33 Time-to-event end-point analyses were performed by using the Kaplan-Meier method. We categorized subjects into 4 groups according to the cutoff value of FMD and the cutoff value of nitroglycerine-induced vasodilation. Cutoff values were derived from the receiver-operator characteristic curves. A log-rank test was used to compare survival in the groups. A post hoc power analysis was performed to assess the adequacy of sample size using the observed cohort size. As the primary analysis, we evaluated the associations between FMD combined with nitroglycerine-induced vasodilation and first major cardiovascular events after adjustment for age, sex, and cardiovascular risk factors by using Cox proportional hazard regression analysis. Multiplicity was controlled with a step-down closed testing procedure for the first major cardiovascular events with the following comparisons: group 1 versus group 4, group 1 versus group 2, group 1 versus group 3. As the sensitivity analysis, we performed exploratory analysis to evaluate the prognostic value of FMD combined with nitroglycerine-induced vasodilation before and after adjustment for age and sex. In a second sensitivity analysis, the proportional hazards assumption was confirmed by inspection of Schoenfeld residuals and log-log plotting. In a third sensitivity analysis, the increased discriminative value of FMD combined with nitroglycerine-induced vasodilation was further examined by using the net reclassification improvement (NRI). 34 Subjects were initially stratified as low-risk, intermediate-risk, and high-risk groups according to the Framingham risk score: low risk (0 to <6%), intermediate risk (6% to 20%), and high risk (>20%). Subjects could then be reclassified into different categories with the addition of data for FMD combined with nitroglycerine-induced vasodilation. We assessed the number of subjects reclassified and also calculated NRI. The data were processed using the software package Stata, version 9 (Stata Co, College Station, TX).
Results
Baseline Clinical Characteristics
The baseline characteristics of the 402 subjects are summarized in 
First Major Cardiovascular Events
During a median period of 32.3 months (interquartile range, 17.1-49.1 months) of follow-up, 15 subjects died (5 from cardiovascular causes), 3 had myocardial infarction, 7 had stroke, 26 had coronary revascularization, and 8 were hospitalized for heart failure ( Table 2) Table S1 ) and that of FMD compared with nitroglycerine-induced vasodilation was 0.138 (P=0.038; Table S2 ).
FMD and Clinical Events
The subjects were divided into 3 tertiles based on FMD. The high group had FMD of ≥5.3%, the intermediate group had FMD between 3.0% and 5.2%, and the low group had FMD Table S3 . There were significant differences between the Kaplan-Meier curves for first major cardiovascular events (P<0.001; Figure S1 ). There were significant differences between the Kaplan-Meier curves for coronary revascularization (P=0.02), but there were no significant differences between the Kaplan-Meier curves for death from cardiovascular disease (P=0.22), acute myocardial infarction (P=0.34), stroke (P=0.10), hospitalization for heart failure (P=0.07), and death from any cause (P=0.07; Figure  S2 ). Clinical outcomes of all subjects on the basis of FMD are shown in Table S4 . After adjustment for age, sex, BMI, and cardiovascular risk factors, the associations between low levels of FMD and increasing risk of first major cardiovascular events (hazard ratio, 3.31; 95% CI, 1.10-14.32; P=0.03) remained significant (Table S5) .
Nitroglycerine-Induced Vasodilation and Clinical Events
We next categorized subjects into 3 tertiles based on nitroglycerine-induced vasodilation. The high group had nitroglycerine-induced vasodilation of ≥14.4%, the intermediate group had nitroglycerine-induced vasodilation between 9.8% and 14.3%, and the low group had nitroglycerineinduced vasodilation of ≤9.7%. Clinical characteristics of the subjects on the basis of nitroglycerine-induced vasodilation are summarized in Table S6 . There were significant differences between the Kaplan-Meier curves for first major cardiovascular events (P<0.001; Figure S3 ). There were significant differences between the Kaplan-Meier curves for death from cardiovascular disease (P=0.002), stroke (P=0.03), coronary revascularization (P=0.03), hospitalization for heart failure (P=0.01), and death from any cause (P=0.02), but there was no significant difference between the Kaplan-Meier curves for acute myocardial infarction (P=0.41; Figure S4 ). Clinical outcomes of all subjects on the basis of nitroglycerine-induced vasodilation are shown in Table S7 . After adjustment for age, sex, BMI, and cardiovascular risk factors, the associations between low levels of nitroglycerine-induced vasodilation and increasing risk of first major cardiovascular events (hazard ratio, 3.60; 95% CI, 1.32-12.65; P=0.01) remained significant (Table S8) .
FMD Combined with Nitroglycerine-Induced Vasodilation and Clinical Events
Because there is no previous study investigating the association between FMD combined with nitroglycerine-induced vasodilation and cardiovascular event, we categorized subjects into 4 groups according to the cutoff value of FMD and the cutoff value of nitroglycerine-induced vasodilation (Table 1) . Group 1 had FMD of ≥3.3% and nitroglycerineinduced vasodilation of ≥11.6%, group 2 had FMD of ≥3.3% and nitroglycerine-induced vasodilation of <11.6%, group 3 had FMD of <3.3% and nitroglycerine-induced vasodilation of ≥11.6%, and group 4 had FMD of <3.3% and nitroglycerine-induced vasodilation of <11.6%. There were significant differences between the Kaplan-Meier curves for first major cardiovascular events (P<0.001; Figure) . There were significant differences between the Kaplan-Meier curves for death from cardiovascular disease (P=0.04), coronary revascularization (P<0.001), hospitalization for heart failure (P=0.04), and death from any cause (P=0.03), but there were no significant differences between the Kaplan-Meier curves for acute myocardial infarction (P=0.75) and stroke (P=0.06; Figure S5 ). After adjustment for age, sex, BMI, and cardiovascular risk factors, above cutoff FMD and below cutoff nitroglycerineinduced vasodilation (hazard ratio, 5.55; 95% CI, 1.61-25.46; P=0.006) and below cutoff FMD and below cutoff nitroglycerine-induced vasodilation (hazard ratio, 7.20; 95% CI, 2.37-31.36; P<0.001) remained strong independent indicators of cardiovascular events (Table 3) .
Reclassification for subjects who developed first major cardiovascular events and for those who did not develop first major cardiovascular events is summarized in Table 4 . For 8 subjects in whom first major cardiovascular events occurred, reclassification was more accurate when the model with FMD combined with nitroglycerine-induced vasodilation was used, and for 5 subjects, it became less accurate. Among the subjects in whom first major cardiovascular events did not occur, 101 were reclassified in a lower-risk category and 28 were reclassified in a higher-risk category. The NRI was 0.286 (P=0.002). 
Discussion
In the present study, we demonstrated for the first time that nitroglycerine-induced vasodilation of the brachial artery was independently associated with future cardiovascular events, including healthy subjects and patients with cardiovascular disease and that combination of FMD and nitroglycerineinduced vasodilation measurements improved the prognostic value of first major cardiovascular events. In addition, we confirmed that a combination of FMD and nitroglycerine-induced vasodilation significantly adds to the predictive value of the Framingham risk score. Both measurements of FMD and nitroglycerine-induced vasodilation are recommended to maximize the long-term predictive value for cardiovascular events.
Several investigators have also reported that decreased FMD is an independent predictor of future cardiovascular events in patients with hypertension, coronary artery disease, chronic heart failure, peripheral arterial disease, and metabolic syndrome. [17] [18] [19] [20] [21] [22] However, some studies have shown that FMD is not associated with incidence of cardiovascular events. 28, 29 In the present study, first major cardiovascular events were significantly more frequent among patients with low levels of FMD than among those with high levels. In addition, after adjustment for age, sex, BMI, and cardiovascular risk factors, there was significant association between FMD and increasing risk of first major cardiovascular events. It is well known that various factors affect FMD. Because both endogenous NO and exogenous NO act on vascular smooth muscle cells, the administration of exogenous nitrate has been used to separate the existence of vascular smooth muscle cell dysfunction versus endothelial dysfunction. Although measurement of FMD is in widespread research tool, it remains unclear whether FMD provides additional information beyond traditional cardiovascular risk factors. 28, 29, 35 Previous studies have confirmed that measurement of FMD is useful for detecting the early stage of atherosclerosis and is a therapeutic marker for atherosclerosis.
36,37 However, we cannot deny the possibility that only measurement of FMD is an insufficient biomarker for future cardiovascular events.
In the present study, multivariate regression analysis revealed that the combination of below cutoff FMD and above cutoff nitroglycerine-induced vasodilation was not associated with incidence of first major cardiovascular events and that below cutoff nitroglycerine-induced vasodilation independent of the cutoff value of FMD remained an independent predictor of first major cardiovascular events. We previously reported that FMD is decreased in subjects at the early stage of atherosclerosis, whereas nitroglycerine-induced vasodilation is maintained in subjects at the early stage of atherosclerosis, but nitroglycerine-induced vasodilation is decreased in subjects with advanced atherosclerosis or established cardiovascular disease. 27, 38, 39 Previous studies have shown that nitroglycerineinduced vasodilation may reflect not only arterial stiffness and vascular structure but also vascular function. [25] [26] [27] These findings suggested a difference between the potential utility Figure. Kaplan-Meier curves of cumulative event-free survival of first major cardiovascular events (death from cardiovascular causes, myocardial infarction, stroke, and revascularization) in subgroups of subjects categorized as being above or below the cutoff values for flow-mediated vasodilation (FMD) and nitroglycerine-induced vasodilation. Group 1 indicates FMD≥3.3% and nitroglycerine-induced vasodilation≥11.6%; Group 2: FMD≥3.3% and nitroglycerine-induced vasodilation<11.6%; Group 3: FMD<3.3% and nitroglycerineinduced vasodilation≥11.6%; and Group 4: FMD<3.3% and nitroglycerine-induced vasodilation<11.6%. The P value was calculated from the log-rank test. First major cardiovascular events include death from cardiovascular disease, acute myocardial infarction, stroke, and coronary revascularization. FMD indicates flow-mediated vasodilation. Group 1 indicates FMD≥3.3% and nitroglycerine-induced vasodilation≥11.6%; Group 2: FMD≥3.3% and nitroglycerine-induced vasodilation<11.6%; Group 3: FMD<3.3% and nitroglycerine-induced vasodilation≥11.6%; and Group 4: FMD<3.3% and nitroglycerine-induced vasodilation<11.6%.
*Adjusted for age and sex. †Adjusted also for age; sex; body mass index; the presence of hypertension, dyslipidemia, and diabetes mellitus; and current smoking. of FMD and that of nitroglycerine-induced vasodilation and the usefulness of simultaneous measurements of FMD and nitroglycerine-induced vasodilation to evaluate the degree of atherosclerosis. FMD combined with nitroglycerine-induced vasodilation more effectively predicts future cardiovascular events than does FMD alone or nitroglycerine-induced vasodilation alone. Previously, FMD was shown to provide significant improvement in the reclassification of subjects as low, intermediate, or high risk compared with the Framingham risk score alone. 40 However, it is not clear whether a combination of FMD and nitroglycerine-induced vasodilation measurements adds value to the Framingham risk scores for prediction of cardiovascular events. In the present study, we showed that a combination of FMD and nitroglycerine-induced vasodilation measurements increased the net reclassification index for risk categories based on the Framingham risk score (P=0.002). On the contrary, we found that the NRI of FMD compared with nitroglycerine-induced vasodilation was significantly increased (P=0.038), although the NRI of nitroglycerine-induced vasodilation compared with the FMD was not increased (P=0.063). These findings suggest that measurement of nitroglycerine-induced vasodilation may compensate for shortcomings of FMD measurement and that nitroglycerine-induced vasodilation should be measured for incremental prediction of cardiovascular events compared with FMD measurements alone.
Study Limitations
First, the study groups were not homogeneous, and the number of events, especially stroke and acute myocardial infarction, during the follow-up period was relatively small. However, our results have clearly shown that FMD combined with nitroglycerine-induced vasodilation improves the ability for prediction of future cardiovascular events. A multicenter study in a larger population is needed to confirm the prognostic value of FMD combined with nitroglycerine-induced vasodilation. Second, we used a cohort of subjects who had varying degrees of health. This cohort had a low incidence of obesity, which is also a strong predictor of cardiovascular health. In this study, 106 of the 402 subjects were overweight or obese (defined as BMI ≥25 kg/m 2 ). We categorized overweight or obese subjects into 4 groups according to the cutoff value of FMD and the cutoff value of nitroglycerineinduced vasodilation. There were significant differences between the Kaplan-Meier curves for first major cardiovascular events in overweight and obese subjects, and obese subjects (P<0.001; Figure S6 ). Of the 106 subjects who were overweight or obese, 23 were obese (defined as BMI ≥30 kg/m 2 ). First major cardiovascular events occurred in 2 of the 4 subjects in the group (FMD <3.1% and nitroglycerine-induced vasodilation <6.3%). There were no first major cardiovascular events in the other groups (FMD ≥3.1% and nitroglycerine-induced vasodilation ≥6.3%, FMD ≥3.1% and nitroglycerine-induced vasodilation <6.3%, and FMD <3.1% and nitroglycerine-induced vasodilation ≥6.3%). In the obese group, appropriate statistical analysis could not be performed because of the small number of subjects. Third, in the present study, we collected the information on potential outcomes or adverse events from medical records and from 1 telephone survey. Regularly scheduled prospective follow-up visits would be ideal to collect prognostic information. Fourth, we measured FMD and nitroglycerine-induced vasodilation just one time when the subjects were enrolled. Repeated measurements of FMD combined with nitroglycerine-induced vasodilation will enable specific conclusions concerning the role of integrative assessment of vascular function in future cardiovascular events to be drawn. In addition, repeated measurements of FMD combined with nitroglycerine-induced vasodilation may be more useful to confirm the therapeutic efficacy for prevention of cardiovascular events. Fifth, mitochondrial aldehyde dehydrogenase 2 (ALDH2) is involved in the bioactivation of nitroglycerine. An ALDH2 variant, ALDH2*504Lys, exists primarily in East Asians, including Japanese with frequencies as high as 40%.
41 ALDH2*504Lys inhibits the activity of ALDH2 in heterozygotes and abolishes the activity in homozygotes. However, we did not investigate ALDH2 genotype of the subjects. Therefore, we cannot deny the possibility that subjects with the ALDH2 variant were included in this study and that their responses to nitroglycerine were influenced by reduced bioactivation of nitroglycerine. Sakata et al 42 showed that nitroglycerineinduced vasodilation did not differ among ALDH2 genotypes, suggesting that ALDH2 genotypes might have little influence on the results of this study.
In conclusion, the combination of below cutoff values of FMD and nitroglycerine-induced vasodilation was associated with the highest incidence of cardiovascular events, suggesting that FMD combined with nitroglycerine-induced vasodilation may be useful as a surrogate marker of future cardiovascular events. Measurement of nitroglycerine-induced vasodilation provided additional information on the pathogenesis of atherosclerosis beyond the control test for FMD. Furthermore, 
Perspectives
Nitroglycerine-induced vasodilation was independently associated with future cardiovascular events. The combination of FMD and nitroglycerine-induced vasodilation measurements improved the prognostic value of first major cardiovascular events than measurement of FMD alone. Nitroglycerine-induced vasodilation should be measured for incremental prediction of cardiovascular events compared with FMD measurements alone.
Supplemental Methods
Measurement of FMD and Nitroglycerine-induced Vasodilation
Vascular response to reactive hyperemia in the brachial artery was used for assessment of endothelium-dependent FMD. A high-resolution linear artery transducer was coupled to computer-assisted analysis software (UNEXEF18G, UNEX Co, Nagoya, Japan) that used an automated edge detection system for measurement of brachial artery diameter. A blood pressure cuff was placed around the forearm. The brachial artery was scanned longitudinally 5-10 cm above the elbow. When the clearest B-mode image of the anterior and posterior intimal interfaces between the lumen and vessel wall was obtained, the transducer was held at the same point throughout the scan by a special probe holder (UNEX Co) to ensure consistency of the image. Depth and gain setting were set to optimize the images of the arterial lumen wall interface. When the tracking gate was placed on the intima, the artery diameter was automatically tracked, and the waveform of diameter changes over the cardiac cycle was displayed in real time using the FMD mode of the tracking system. This allowed the ultrasound images to be optimized at the start of the scan and the transducer position to be adjusted immediately for optimal tracking performance throughout the scan. Pulsed Doppler flow was assessed at baseline and during peak hyperemic flow, which was confirmed to occur within 15 s after cuff deflation. Blood flow velocity was calculated from the color Doppler data and was displayed as a waveform in real time. The baseline longitudinal image of the artery was acquired for 30 s, and then the blood pressure cuff was inflated to 50 mm Hg above systolic pressure for 5 min. The longitudinal image of the artery was recorded continuously until 5 min after cuff deflation. Pulsed Doppler velocity signals were obtained for 20 s at baseline and for 10 s immediately after cuff deflation. Changes in brachial artery diameter were immediately expressed as percentage change relative to the vessel diameter before cuff inflation. FMD was automatically calculated as the percentage change in peak vessel diameter from the baseline value. Percentage of FMD [(Peak diameter-Baseline diameter)/Baseline diameter] was used for analysis. Blood flow volume was calculated by multiplying the Doppler flow velocity (corrected for the angle) by heart rate and vessel cross-sectional area (-r 2 ). Reactive hyperemia was calculated as the maximum percentage increase in flow after cuff deflation compared with baseline flow. The coefficient of variation for FMD was 10.1% in our laboratory.
The response to nitroglycerine was used for assessment of endothelium-independent vasodilation. Nitroglycerine-induced vasodilation was measured as described previously. Briefly, after acquiring baseline rest images for 30 s, a sublingual tablet (75 μg nitroglycerine) was given, and images of the artery was recorded continuously until the dilation reached a plateau after administration of nitroglycerine. Subjects who had received nitrate treatment and subjects in whom the sublingually administered nitroglycerine tablet was not dissolved during the measurement were excluded from this study. Nitroglycerine-induced vasodilation was automatically calculated as a percent change in peak vessel diameter from the baseline value. Percentage of nitroglycerine-induced vasodilation [(Peak diameter-Baseline diameter)/Baseline diameter] was used for analysis. Tables   Table S1 . Reclassification of FMD after Addition of Nitroglycerine-induced Vasodilation First major cardiovascular events include death from cardiovascular disease, acute myocardial infarction, stroke, and coronary revascularization. FMD indicates flow-mediated vasodilation. The net reclassification improvement was 0.126 (P=0.063). 
Supplemental
Model with FMD
Model with FMD and nitroglycerine-induced vasodilation <6% risk 6-20% risk >20% risk Number of participants Participants with first major cardiovascular events <6% risk 3 0 0 6-20% risk 3 26 6 >20% risk 0 0 0 Participants without first major cardiovascular events <6% risk 90 16 0 6-20% risk 51 179 22 >20% risk 1 3 2
Supplementary Figures
Figure S1
Figure S1. Kaplan-Meier curves of cumulative event-free survival of first major cardiovascular events (death from cardiovascular causes, myocardial infarction, stroke, and revascularization) according to flow-mediated vasodilation (FMD). The P value was calculated from the log-rank test. 
